A modified anticancer drug can simultaneously target tumour sites and show whether or not it is working.
Cancer drugs can be modified to specifically target tumour sites to help personalize cancer treatment. And while it is relatively easy to determine if the drugs have been delivered to the correct location, it is more difficult to monitor their therapeutic success.
A modified platinum-based prodrug targets cancer cells and triggers cell death, or apoptosis, causing apoptosis sensors to fluoresce green.
Now, a team led by Bin Liu from the A*STAR Institute of Materials Research and Engineering in Singapore, in collaboration with Ben Zhong Tang at Hong Kong University of Science and Technology, has developed an anticancer drug with an inbuilt mechanism that shows if it is working.
Platinum-based drugs are effective against many cancers, killing cells by triggering cellular suicide, or apoptosis. These drugs can, however, have severe side effects. Nontoxic forms can be modified, as a type of prodrug, to convert to their toxic form only after entering the targeted tumour cells, so as not to harm noncancerous cells.
Liu and colleagues went one step further by modifying a platinum-based prodrug to not only target tumor cells effectively, but also show whether or not it was having the desired effect. According to Liu, this added feature could be crucial for improving cancer treatment.
“Early evaluation of a patient’s response to a specific cancer therapy is important in clinical applications because it can minimize the duration of ineffective courses,” explains Liu. “The effectiveness of cancer treatment is commonly evaluated using magnetic resonance imaging to measure the tumor size, but this is unsatisfactory as the change in size is not obvious at the early stages of therapy.”
In their new system, Liu and her team included an apoptosis sensor that is released when the prodrug converts to its toxic form inside the targeted tumor cells. The toxic form triggers cell apoptosis and activates an enzyme called caspase 3, which then cleaves the apoptosis sensor and causes it to fluoresce green. This provides a visual signal that the drug is killing the cells.
Liu and her colleagues tested the mechanism by treating cultured cancer cells with the modified platinum prodrug. They observed a gradual increase in fluorescence in the cancer cells, reaching a maximum level of fluorescence six hours after treatment. Noncancerous cells were not affected in the same way, further proving the effectiveness of their targeting mechanism.
Such noninvasive and real-time imaging of drug-induced apoptosis could be used to evaluate the therapeutic response to a specific anticancer drug at an early stage, explains Liu. “Our system can simultaneously deliver the therapeutic drugs and noninvasively evaluate the therapeutic responses in situ.”
1. Yuan, Y., Kwok, R. T. K., Tang, B. Z., Liu, B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. Journal of the American Chemical Society 136, 2546–2554 (2014).
Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University
How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy